The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for chronic weight management.1

After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.1

The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose.1

The recommended maintenance dosages of tirzepatide in adults are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.1

Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.1 

The maximum dosage of tirzepatide is 15 mg injected subcutaneously once weekly.1

Prior to initiation, patients and caregivers must be trained on proper injection technique and how to set the syringe for appropriate dose administration.1

Administer tirzepatide

• once weekly
• any time of day, and
• with or without food.1

Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm and injection sites should be rotated with each dose.1

The global phase 3 SURMOUNT clinical program evaluated tirzepatide 5, 10, and 15 mg dosages for safety and efficacy. These doses and associated dose-escalation schemes (Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies) were based on the assessment of safety, efficacy, and gastrointestinal tolerability data from phase 1 and 2 studies.